DNM3 (dynamin 3) is a GTPase protein that functions primarily in vesicular trafficking processes, particularly endocytosis and synaptic vesicle budding 1. The protein exhibits microtubule-associated force-producing properties and can bind and hydrolyze GTP to facilitate membrane fission and scission processes. DNM3 shows distinctive tissue-specific expression patterns, with classical dynamin genes DNM1 and DNM3 reaching maximum expression levels (100%) specifically in normal human central nervous system tissues, compared to approximately 50% expression in other organs 1. This CNS-enriched expression profile suggests a specialized role in synaptic function and neuronal processes. In disease contexts, DNM3 variants have been investigated as potential genetic modifiers in Parkinson's disease, though results remain inconclusive with possible population-specific effects 23. The gene has also been implicated in multiple sclerosis progression, where variants in the DNM3-PIGC locus show suggestive associations with disease severity 4. Additionally, DNM3 serves as a diagnostic biomarker in Sézary syndrome, a cutaneous T-cell lymphoma, where it is significantly overexpressed and helps differentiate this condition from other lymphomas 5. Recent proteomic studies have identified DNM3 as part of cerebrospinal fluid protein signatures in frontotemporal lobar degeneration 6.